Transforming biosimilar switches for the NHS
Biosimilar switches can save the NHS millions, but administrative burden often delays these savings by months. This case study, published in PM Healthcare Journal, details how Sciensus and Gloucestershire Hospitals NHS Foundation Trust co-designed an automated service that transformed biosimilar transitions while removing the prescribing and administrative burden from NHS teams.
The result: A biosimilar switch completed in 3 months instead of 6-12 months, unlocking an additional £500k in savings.
What you’ll learn:
- How automated prescribing using Sciensus pharmacists removes NHS administrative burden
- Time savings: 75+ hours saved per 650 patients
- Performance data: 92.5% biosimilar uptake at GHFT vs 52.8% nationally
- The governance framework ensuring patient safety
- How digital systems enable seamless switching while NHS clinicians focus on patient care
Download the full case study published in PM Healthcare Journal, a peer-reviewed quarterly publication sharing UK-wide best practice and innovation in pharmacy and healthcare.
About Sciensus
Sciensus is a European leader in integrated end-to-end commercial services, supporting patients, health systems, providers and Biopharma companies. We offer distribution services, clinical care, digital solutions and patient insights to accelerate access to medicines and maximise product launches from clinical to full commercialisation. With over 30 years’ experience navigating the complex European healthcare ecosystem, Sciensus helps bring the right medicine to the right patients – faster.